Moderna, Inc. (NASDAQ:MRNA) Position Increased by Bessemer Group Inc.

Bessemer Group Inc. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 133.9% in the 1st quarter, Holdings Channel reports. The firm owned 11,604 shares of the company’s stock after purchasing an additional 6,642 shares during the quarter. Bessemer Group Inc.’s holdings in Moderna were worth $329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in MRNA. US Bancorp DE increased its stake in Moderna by 13.2% during the fourth quarter. US Bancorp DE now owns 16,962 shares of the company’s stock valued at $705,000 after purchasing an additional 1,981 shares during the last quarter. Metis Global Partners LLC increased its stake in Moderna by 35.3% during the fourth quarter. Metis Global Partners LLC now owns 20,076 shares of the company’s stock valued at $835,000 after purchasing an additional 5,242 shares during the last quarter. Modera Wealth Management LLC bought a new stake in Moderna during the fourth quarter valued at $231,000. Jones Financial Companies Lllp increased its stake in Moderna by 113.3% during the fourth quarter. Jones Financial Companies Lllp now owns 14,841 shares of the company’s stock valued at $617,000 after purchasing an additional 7,883 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Moderna by 9.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock valued at $97,472,000 after purchasing an additional 211,426 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent research reports. Morgan Stanley lowered their price target on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Evercore ISI lowered their price target on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research report on Friday, May 2nd. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Citigroup started coverage on shares of Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating for the company in a report on Thursday, May 22nd. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $46.61.

Moderna Trading Up 5.5%

MRNA stock opened at $30.28 on Thursday. Moderna, Inc. has a one year low of $23.15 and a one year high of $129.39. The firm has a market capitalization of $11.71 billion, a PE ratio of -3.47 and a beta of 1.84. The firm has a 50-day moving average of $26.59 and a two-hundred day moving average of $31.60.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The firm’s quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.07) EPS. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.